-
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-S
Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable and durable efficacy of tralokinumab in adult patients1 Patients enrolled in ECZTRA 1 and 2 parent tr…- 30
- 0
-
$优惠劵使用时效：无法使用使用时效：
之前
使用时效：永久有效优惠劵ID：×